Apellis Pharmaceuticals Inc.(APLS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

APLS Apellis Pharmaceuticals Inc.

休市中 05-17 16:00:00 EDT

41.31

-0.69

-1.64%

盘后41.28

-0.03-0.07%

19:51 EDT

最高42.42	最低41.16	成交量86.66万
今开42.00	昨收42.00	日振幅3.00%
总市值50.14亿	流通市值33.83亿	总股本1.21亿
成交额3,602万	换手率1.06%	流通股本8,191万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"APLS","market":"US","secType":"STK","nameCN":"Apellis Pharmaceuticals Inc.","latestPrice":41.31,"timestamp":1715976000000,"preClose":42,"halted":0,"volume":866626,"hourTrading":{"tag":"盘后","latestPrice":41.28,"preClose":41.31,"latestTime":"19:51 EDT","volume":12965,"amount":535843.1,"timestamp":1715989896236},"delay":0,"floatShares":81905037,"shares":121365555,"eps":-3.449984,"marketStatus":"休市中","marketStatusCode":7,"change":-0.69,"latestTime":"05-17 16:00:00 EDT","open":42,"high":42.42,"low":41.16,"amount":36015693.95352,"amplitude":0.03,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.449984,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1716192000000},"adr":0,"listingDate":1510203600000,"adjPreClose":42,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":41.93,"preClose":42,"latestTime":"09:29 EDT","volume":1818,"amount":76428.32004,"timestamp":1715952599999},"postHourTrading":{"tag":"盘后","latestPrice":41.28,"preClose":41.31,"latestTime":"19:51 EDT","volume":12965,"amount":535843.1,"timestamp":1715989896236},"volumeRatio":0.6354240560189895,"optionData":{"bulkOrders":[{"symbol":"APLS","call":true,"expireDate":1718942400000,"strike":"45.0","timestamp":1715973465034,"price":1.899999976158142,"volume":1500,"amount":285000,"type":"+"},{"symbol":"APLS","call":false,"expireDate":1715918400000,"strike":"45.0","timestamp":1715973465034,"price":3.700000047683716,"volume":1500,"amount":555000,"type":"*"}]}},"requestUrl":"/m/hq/s/APLS/tweets","defaultTab":"tweets","newsList":[{"id":"2436992749","title":"美国研究综述-Bath & Body Works、Under Armour、Viking Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2436992749","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2436992749?lang=zh_cn&edition=full","pubTime":"2024-05-17 18:51","pubTimestamp":1715943108,"startTime":"0","endTime":"0","summary":"    路透5月17日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括 Bath & Body Works、Under Armour 和 Viking Therapeutics。要闻  * Advanced Drainage Systems Inc   ：巴克莱将目标价从189美元上调至202美元             * Bath & Body Works Inc   ：摩根大通将其评级从 \"减持 \"上调至 \"中性\"。* Under Armour Inc   ：摩根大通将其评级从 \"中性 \"下调至 \"减持\"。* Viking Therapeutics Inc   ：Raymond James将其评级从 \"跑赢大盘 \"上调至 \"强力买入\"。* Abbvie Inc   ：Cantor Fitzgerald给予该公司 \"增持 \"评级，目标价200美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2436969363","title":"美国研究综述-迪尔公司、Under Armour、沃尔玛","url":"https://stock-news.laohu8.com/highlight/detail?id=2436969363","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2436969363?lang=zh_cn&edition=full","pubTime":"2024-05-17 14:56","pubTimestamp":1715928964,"startTime":"0","endTime":"0","summary":"    路透5月17日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括迪尔公司、Under Armour 和沃尔玛。要闻              * Advanced Drainage Systems Inc   ：巴克莱将其目标价从189美元上调至202美元             * 迪尔公司  ：大和资本市场将目标价从400美元上调至440美元             * Under Armour Inc   ：摩根大通将其评级从 \"中性 \"下调至 \"减持\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2435702493","title":"Apellis Pharmaceuticals, Inc.2024财年第一财季实现净利润-66.42百万美元，同比增加62.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2435702493","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2435702493?lang=zh_cn&edition=full","pubTime":"2024-05-14 00:24","pubTimestamp":1715617442,"startTime":"0","endTime":"0","summary":"3月31日，Apellis Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第一财季净利润为-66.42百万美元，同比增加62.69%；其中营业收入为1.72亿美元，同比增加283.50%，每股基本收益为-0.54美元。从资产负债表来看，Apellis Pharmaceuticals, Inc.总负债5.65亿美元，其中短期债务83.54百万美元，资产负债比为1.48，流动比率为3.78。机构评级：截至2024年3月31日，当前有17家机构对Apellis Pharmaceuticals, Inc.目标价做出预测，其中目标均价为80.54美元，其中最低目标价为50.00美元，最高目标价为116.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405140024118b02725c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405140024118b02725c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434577065","title":"HC Wainwright & Co.：重申Apellis Pharmaceuticals(APLS.US)评级，由买入调整至买入评级, 目标价92.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2434577065","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2434577065?lang=zh_cn&edition=full","pubTime":"2024-05-09 03:15","pubTimestamp":1715195737,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：重申Apellis Pharmaceuticals(APLS.US)评级，由买入调整至买入评级, 目标价92.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050903154087e16a7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050903154087e16a7b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433201957","title":"Apellis Pharmaceuticals, Inc.盘中异动 急速下跌5.01%报41.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2433201957","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2433201957?lang=zh_cn&edition=full","pubTime":"2024-05-08 22:57","pubTimestamp":1715180275,"startTime":"0","endTime":"0","summary":"北京时间2024年05月08日22时57分，Apellis Pharmaceuticals, Inc.股票出现异动，股价大幅下跌5.01%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.19%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405082257567a58c5f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405082257567a58c5f1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433450788","title":"Apellis Pharmaceuticals, Inc.盘中异动 股价大跌7.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2433450788","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2433450788?lang=zh_cn&edition=full","pubTime":"2024-05-07 21:30","pubTimestamp":1715088623,"startTime":"0","endTime":"0","summary":"北京时间2024年05月07日21时30分，Apellis Pharmaceuticals, Inc.股票出现波动，股价急速下跌7.60%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.44%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240507213023861eb743&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240507213023861eb743&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432662901","title":"Apellis Pharmaceuticals Inc    预计每股亏损 52 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2432662901","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2432662901?lang=zh_cn&edition=full","pubTime":"2024-05-03 22:55","pubTimestamp":1714748139,"startTime":"0","endTime":"0","summary":"   * Apellis Pharmaceuticals Inc    将于5月7日公布截至2024年3月31日的财报，预计该公司的季度收入将有所增长。* LSEG 分析师对 Apellis Pharmaceuticals Inc 的平均预期是每股亏损 52 美分。* 华尔街对 Apellis Pharmaceuticals Inc 的 12 个月目标价中位数为 84.00 美元，高于其上次收盘价 47.49 美元。5月3日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2431267943","title":"Apellis Pharmaceuticals, Inc.盘中异动 股价大跌5.14%报45.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431267943","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431267943?lang=zh_cn&edition=full","pubTime":"2024-04-30 21:45","pubTimestamp":1714484714,"startTime":"0","endTime":"0","summary":"北京时间2024年04月30日21时45分，Apellis Pharmaceuticals, Inc.股票出现波动，股价大幅下挫5.14%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.01%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043021451579258605&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043021451579258605&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430072302","title":"Apellis Pharmaceuticals, Inc.盘中异动 股价大涨5.03%报50.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430072302","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430072302?lang=zh_cn&edition=full","pubTime":"2024-04-26 23:54","pubTimestamp":1714146846,"startTime":"0","endTime":"0","summary":"北京时间2024年04月26日23时54分，Apellis Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.03%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.36%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240426235406861e9966&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240426235406861e9966&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430282069","title":"Apellis Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.05%报47.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430282069","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430282069?lang=zh_cn&edition=full","pubTime":"2024-04-25 22:35","pubTimestamp":1714055747,"startTime":"0","endTime":"0","summary":"北京时间2024年04月25日22时35分，Apellis Pharmaceuticals, Inc.股票出现异动，股价快速下挫5.05%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.84%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404252235487a55b949&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404252235487a55b949&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428378134","title":"Apellis Pharmaceuticals, Inc.盘中异动 下午盘股价大跌5.00%报49.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2428378134","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428378134?lang=zh_cn&edition=full","pubTime":"2024-04-18 03:11","pubTimestamp":1713381116,"startTime":"0","endTime":"0","summary":"北京时间2024年04月18日03时11分，Apellis Pharmaceuticals, Inc.股票出现异动，股价急速跳水5.00%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.60%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。该信息摘要如下：Wedbush：维持Apellis Pharmaceuticals评级，由中性调整至中性评级, 目标价由67.00美元调整至57.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180311567a538294&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180311567a538294&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428326302","title":"Wedbush：维持Apellis Pharmaceuticals(APLS.US)评级，由中性调整至中性评级, 目标价由67.00美元调整至57.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2428326302","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428326302?lang=zh_cn&edition=full","pubTime":"2024-04-18 00:35","pubTimestamp":1713371710,"startTime":"0","endTime":"0","summary":"Wedbush：维持Apellis Pharmaceuticals(APLS.US)评级，由中性调整至中性评级, 目标价由67.00美元调整至57.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180035148b30d71c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180035148b30d71c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426738916","title":"Apellis Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426738916","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426738916?lang=zh_cn&edition=full","pubTime":"2024-04-12 21:52","pubTimestamp":1712929938,"startTime":"0","endTime":"0","summary":"北京时间2024年04月12日21时52分，Apellis Pharmaceuticals, Inc.股票出现异动，股价大幅下跌5.17%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.26%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。该信息摘要如下：Needham：重申Apellis Pharmaceuticals评级，由买入调整至买入评级, 目标价85.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041221521879203ae6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041221521879203ae6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426161509","title":"Needham：重申Apellis Pharmaceuticals(APLS.US)评级，由买入调整至买入评级, 目标价85.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2426161509","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426161509?lang=zh_cn&edition=full","pubTime":"2024-04-09 18:45","pubTimestamp":1712659528,"startTime":"0","endTime":"0","summary":"Needham：重申Apellis Pharmaceuticals(APLS.US)评级，由买入调整至买入评级, 目标价85.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091845298b03185e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091845298b03185e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424007045","title":"Apellis Pharmaceuticals, Inc.盘中异动 快速下挫5.33%报56.53美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2424007045","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2424007045?lang=zh_cn&edition=full","pubTime":"2024-04-02 21:50","pubTimestamp":1712065803,"startTime":"0","endTime":"0","summary":"北京时间2024年04月02日21时50分，Apellis Pharmaceuticals, Inc.股票出现波动，股价快速下跌5.33%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.41%。消息层面，截至21时50分，《Form 144 | Apellis Pharmaceuticals高管拟出售4,000股股份，价值约23.46万美元》资讯为影响Apellis Pharmaceuticals, Inc.的重要信息。该信息摘要如下：根据美国证券交易委员会美东时间4月1日披露的文件，$Apellis Pharmaceuticals $高管Sullivan Timothy Eugene拟于4月1日出售4,000股普通股股份，总市值约23.46万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040221500387e7da23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040221500387e7da23&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422619617","title":"Apellis Pharmaceuticals, Inc.盘中异动 早盘急速拉升5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422619617","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422619617?lang=zh_cn&edition=full","pubTime":"2024-03-26 21:58","pubTimestamp":1711461533,"startTime":"0","endTime":"0","summary":"北京时间2024年03月26日21时58分，Apellis Pharmaceuticals, Inc.股票出现异动，股价大幅上涨5.09%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.27%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240326215853861e1429&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240326215853861e1429&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420309740","title":"Apellis Pharmaceuticals, Inc.盘中异动 股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2420309740","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420309740?lang=zh_cn&edition=full","pubTime":"2024-03-20 21:40","pubTimestamp":1710942001,"startTime":"0","endTime":"0","summary":"北京时间2024年03月20日21时40分，Apellis Pharmaceuticals, Inc.股票出现异动，股价急速跳水5.02%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.77%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240320214001791bbeb6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240320214001791bbeb6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417200459","title":"美国研究综述-树皮、Fleetcor Technologies、特斯拉","url":"https://stock-news.laohu8.com/highlight/detail?id=2417200459","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417200459?lang=zh_cn&edition=full","pubTime":"2024-03-05 14:57","pubTimestamp":1709621845,"startTime":"0","endTime":"0","summary":"    路透社3月5日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Bark、Fleetcor Technologies 和特斯拉。要闻             * Bark Inc   ：杰富瑞将其评级从 \"持有 \"上调至 \"买入\"；将交易价从1.54美元上调至1.9美元。* Fleetcor Technologies Inc   ：贝尔德将其评级上调至 \"跑赢大盘\"。* 特斯拉  ：加拿大皇家银行将目标价从297美元上调至298美元 以下是路透社周二报道的美国公司研究报告摘要。股票条目按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417176870","title":"美国研究综述-CommScope Holding Company、Dutch Bros、Hess","url":"https://stock-news.laohu8.com/highlight/detail?id=2417176870","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417176870?lang=zh_cn&edition=full","pubTime":"2024-03-05 03:21","pubTimestamp":1709580103,"startTime":"0","endTime":"0","summary":"    路透社3月4日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价，其中包括 CommScope Holding Company、Dutch Bros 和 Hess。要点 * CommScope Holding Company   ：摩根大通将其股票评级从中性下调至减持  * 荷兰兄弟  ：Piper Sandler 将其评级从中性上调至增持  * Hess Corp   ：Susquehanna 将目标价从 152 美元上调至 156 美元  * Pioneer Natural Resources Co   ：苏斯克汉纳将目标价从237美元上调至246美元  * United Therapeutics Corp   ：摩根大通将目标价从294美元下调至280美元  以下是路透社周一报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2416957623","title":"Apellis Pharmaceuticals, Inc.盘中异动 急速上涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416957623","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2416957623?lang=zh_cn&edition=full","pubTime":"2024-03-02 00:19","pubTimestamp":1709309967,"startTime":"0","endTime":"0","summary":"北京时间2024年03月02日00时19分，Apellis Pharmaceuticals, Inc.股票出现波动，股价急速上涨5.07%。截至发稿，该股报65.11美元/股，成交量63.3654万股，换手率0.53%，振幅5.61%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为2.44%。其相关个股中，Biovie Inc.、Adial Pharmaceuticals, Inc、Cardiff Oncology, Inc.涨幅较大，Adial Pharmaceuticals, Inc、Enveric Biosciences, Inc.、Jaguar Health, Inc.较为活跃，换手率分别为3700.26%、401.75%、335.02%，振幅较大的相关个股有Biovie Inc.、Pasithea Therapeutics Corp C/Wts 12/08/2026 、Jaguar Health, Inc.，振幅分别为96.77%、81.48%、81.19%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403020019287a489b78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403020019287a489b78&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.apellis.com","stockEarnings":[{"period":"1week","weight":-0.0162},{"period":"1month","weight":-0.1399},{"period":"3month","weight":-0.3994},{"period":"6month","weight":-0.1587},{"period":"1year","weight":-0.5279},{"period":"ytd","weight":-0.3099}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0577},{"period":"3month","weight":0.0599},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.2629},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Apellis Pharmaceuticals, Inc.于2009年9月25日根据德拉华州法律成立。该公司是一家商业阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过在补体级联中的中心蛋白C3水平上抑制补体系统（作为免疫系统的一个组成部分）来治疗具有高度未满足需求的疾病。2023年2月，美国食品药品监督管理局（FDA）批准了SYFOVRE，这是首个获批治疗继发于年龄相关性黄斑变性（GA）的地理萎缩的药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":-0.018331},{"month":2,"riseRate":0.714286,"avgChangeRate":0.056236},{"month":3,"riseRate":0.571429,"avgChangeRate":0.044074},{"month":4,"riseRate":0.714286,"avgChangeRate":0.062825},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.018498},{"month":6,"riseRate":0.833333,"avgChangeRate":0.097286},{"month":7,"riseRate":0.5,"avgChangeRate":-0.121496},{"month":8,"riseRate":1,"avgChangeRate":0.171387},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.124118},{"month":10,"riseRate":0.5,"avgChangeRate":0.026944},{"month":11,"riseRate":0.666667,"avgChangeRate":0.131706},{"month":12,"riseRate":0.857143,"avgChangeRate":0.150428}],"exchange":"NASDAQ","name":"Apellis Pharmaceuticals Inc.","nameEN":"Apellis Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Apellis Pharmaceuticals Inc.(APLS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Apellis Pharmaceuticals Inc.(APLS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Apellis Pharmaceuticals Inc.,APLS,Apellis Pharmaceuticals Inc.股票,Apellis Pharmaceuticals Inc.股票老虎,Apellis Pharmaceuticals Inc.股票老虎国际,Apellis Pharmaceuticals Inc.行情,Apellis Pharmaceuticals Inc.股票行情,Apellis Pharmaceuticals Inc.股价,Apellis Pharmaceuticals Inc.股市,Apellis Pharmaceuticals Inc.股票价格,Apellis Pharmaceuticals Inc.股票交易,Apellis Pharmaceuticals Inc.股票购买,Apellis Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Apellis Pharmaceuticals Inc.(APLS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Apellis Pharmaceuticals Inc.(APLS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}